Stephen Douglas Smith, MD

Seattle Cancer Care Alliance
Associate Professor, Division of Medical Oncology
University of Washington School of Medicine
Associate Professor, Clinical Research Division
Fred Hutchinson Cancer Research Center
Medical Oncology
“Every patient deserves thorough, up-to-date information, compassion and access to cutting-edge therapies through clinical trials.”
— Dr. Smith
Why did you decide to become an oncologist?

I settled on becoming a doctor while studying biology as an undergraduate. I was interested in applying science to directly help people, and I wanted to be part of the revolution in medicine related to advances in molecular biology. Oncology interests me because, more than any other field of medicine, it combines the essential skills of doctoring, the use of rapidly improving treatments and the opportunity to forge deep bonds with patients.

What is your approach to care?

Rapid advancements have turned hematologic cancers into very treatable conditions, but these diseases still require individualized care. My approach is to design a treatment plan tailored to your specific situation, which includes offering you the newest, most promising therapies. I also believe it’s essential to provide you with all the information you need to make the best treatment decisions for yourself. Sharing thorough, up-to-date information to support your decision-making is at the core of our relationship.

Provider background

Specialty: Medical Oncology

Lymphoma and blood disorders

I am a medical oncologist who cares for patients with lymphoma and other blood disorders and a member of the American Society of Hematology and the American Society of Clinical Oncology. My research focuses on developing and testing new drugs for hematologic malignancies. I’m especially interested in how the immune system works and how we can modify it when it goes awry — in particular, how we can use immunotherapies to treat blood-related cancers like lymphomas. I’m hopeful that, through research, we will find better ways to eradicate these diseases. And, for those diseases that we can’t cure, we should be able to control them with well-tolerated medicines over a person’s normal lifespan.

Diseases treated

Education, experience and certifications
Undergraduate Degree
Stanford University
Medical Degree
Keck School of Medicine of USC
Los Angeles County/USC Medical Center, Internal Medicine
Cleveland Clinic Foundation Program, Hematology and Oncology
Board Certification
Hematology, 2008, 2018, American Board of Internal Medicine


Improving outcomes for mantle cell lymphoma
Improving outcomes for mantle cell lymphoma

Seattle Cancer Care Alliance (SCCA) treats more MCL patients than almost any other center in the Pacific Northwest region and offers one of the nation’s most robust portfolios of standard treatments and clinical trials, in partnership with Fred Hutchinson Cancer Research Center and University of Washington Medical Center (UWMC)


Clinical trials

We make promising new treatments available to you through studies called clinical trials led by SCCA doctors. Many of these trials at SCCA have led to FDA-approved treatments and have improved standards of care globally. Together, you and your doctor can decide if a study is right for you.

Study ID:
Complete title
An Expanded Access Protocol for Patients who Completed Study 13-601 and Continue to Clinically Benefit from Cerdulatinib
Study ID:
Complete title
Investigating Response to Therapy, Functional Imaging Results, and Outcomes in Uncommon Lymphomas
Study ID:
A Study of Bendamustine and Rituximab Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated Mantle Cell Lymphoma
Complete title
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP-196) in Subjects with Previously Untreated Mantle Cell Lymphoma


Many of our SCCA physicians conduct ongoing research to improve standards of patient care. Their work is evaluated by other physicians and selected for publication to the United States National Library of Medicine, the largest medical library in the world. See scientific papers this SCCA provider has written.


SCCA providers are often asked to give their medical expertise for press and news publications. Read articles by or about this SCCA provider.

Targeted Therapies Offer New Treatment Options for R/R MZL Across Subtypes

SCCA's Stephen Douglas Smith, MD, recently discussed targeted therapies and treatment options for marginal zone lymphomas, a group of B-cell non-Hodgkin lymphomas. 

Your care team

At SCCA, you receive care from a team of providers with extensive experience in your disease. Your team includes doctors, a team coordinator, a registered nurse, an advanced practice provider and others, based on your needs. You also have access to experts like nutritionists, social workers, acupuncturists, psychiatrists and more who specialize in supporting people with cancer or blood disorders.
Registered nurse (RN)
Registered nurse (RN)
Your nurse manages your care alongside your physician and assists with care procedures and treatments.
Team coordinator (TC)
Team coordinator (TC)
Your team coordinator works closely with you and your physician and serves as your scheduler.


SCCA accepts most national private health insurance plans as well as Medicare. We also accept Medicaid for people from Washington, Alaska, Montana and Idaho. We are working to ensure that everyone, no matter what their financial situation, has access to the care they need.

For providers